Caring Brands, Inc. (NASDAQ:CABR) Sees Large Drop in Short Interest

Caring Brands, Inc. (NASDAQ:CABR) was the target of a large decline in short interest in the month of July. As of July 15th, there was short interest totaling 36,455 shares, a decline of 48.5% from the June 30th total of 70,819 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average trading volume of 85,145 shares, the days-to-cover ratio is currently 0.4 days.

Caring Brands Price Performance

Shares of NASDAQ:CABR opened at $1.56 on Friday. Caring Brands has a fifty-two week low of $0.71 and a fifty-two week high of $5.35. The company has a current ratio of 5.66, a quick ratio of 5.62 and a debt-to-equity ratio of 0.03. The company has a 50-day moving average price of $1.28. The stock has a market capitalization of $14.18 million and a P/E ratio of -2.44.

Caring Brands (NASDAQ:CABR) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.27) EPS for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Caring Brands from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Caring Brands stock. Jane Street Group LLC bought a new position in shares of Caring Brands, Inc. (NASDAQ:CABR) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands as of its most recent filing with the SEC.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.